Market Place
Sourcing Support
Sumitomo Pharma Announces Availability of ORGOVYX® (relugolix) in Canada
12 Mar 2024 //
PR NEWSWIRE
Sumitomo announces authorization in Canada of Orgovyx for prostate cancer
25 Oct 2023 //
INDIAN PHARMA POST
Sumitomo Pharma Announces Authorization in Canada of ORGOVYX
23 Oct 2023 //
PR NEWSWIRE
Gedeon`s Ryeqo (Relugolix) Receives Approval in Europe
08 Jun 2023 //
EMA
Relugolix Combination Therapy Effective for Heavy Menstrual Bleeding
17 Oct 2022 //
FIRSTWORLDPHARMA
Myovant, Pfizer`s Myfembree nabs FDA nod for endometriosis
09 Aug 2022 //
FIERCEPHARMA
Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE
05 Aug 2022 //
GLOBENEWSWIRE
Myovant touts Pfizer-partnered drug launch plans
30 Jul 2022 //
FIERCEPHARMA
Myovant Sciences Generic Orgovyx (Relugolix) Receives Approval in Europe
10 Jun 2022 //
EMA
ORGOVYX Now Available from Onco360 for Advanced Prostate Cancer
06 Jun 2022 //
BUSINESSWIRE
Myovant and Accord Healthcare enter licence agreement to commercialise Orgovyx
13 May 2022 //
EXPRESS PHARMA
Myovant Stumbles on FDA Concerns Over Pfizer-Partnered Endometriosis Drug
12 Apr 2022 //
BIOSPACE
Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX (relugolix)
25 Feb 2022 //
GLOBENEWSWIRE
MHRA licenses Ryeqo for symptoms of uterine fibroids
26 Oct 2021 //
PHARMATIMES
MHRA licenses uterine fibroid treatment for women in Great Britain
25 Oct 2021 //
PHARMAFILE
FDA accepts sNDA from Myovant Sciences and Pfizer for MYFEMBREE
09 Sep 2021 //
GLOBENEWSWIRE
Gedeon Richter`s Ryeqo Receives Approval in Europe
29 Jul 2021 //
EMA
Relugolix Combination Therapy Reduces Pain in Women With Endometriosis
02 Jul 2021 //
FIRSTWORDPHARMA
Myovant adds relugolix data in uterine fibroids ahead of June PDUFA
26 Mar 2021 //
ENDPTS
Myovant leans on partner Pfizer as it dives into Orgovyx launch
26 Jan 2021 //
FIERCE PHARMA
Myovant Sciences Presents Additional Data on Relugolix Combination Therapy
22 Oct 2020 //
PRESS RELEASE
Myovant shows disappointing prostate cancer data on the way to the FDA
30 Sep 2020 //
ENDPTS
Myovant shows disappointing prostate cancer data on the way to the FDA
29 Sep 2020 //
ENDPTS
Myovant Sciences Announces FDA Acceptance of NDA for Once-Daily Relugolix
17 Aug 2020 //
MYOVANT
Myovant Sciences Presents Additional Data on Relugolix Combination Therapy Ph3
06 Jul 2020 //
MYOVANT
Myovant`s relugolix hits all key goals of second late-stage study for endometriosis-associated pain
24 Jun 2020 //
PRESS RELEASE
Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone
22 Jun 2020 //
GLOBENEWSWIRE
Sumitovant Announces Priority Review & FDA Acceptance of Myovant Sciences
22 Jun 2020 //
GLOBENEWSWIRE
Looking at a groundbreaking advance, Myovant gets a priority review at FDA
22 Jun 2020 //
ENDPTS
Myovant Sciences Submits NDA to the FDA for Once-Daily Relugolix Combination
01 Jun 2020 //
PRESS RELEASE
Myovant Sciences Announces Additional Positive Efficacy & Cardiovascular Safety
29 May 2020 //
PRESS RELEASE
Myovant details speedy effects of prostate cancer med relugolix
29 May 2020 //
FIERCEBIOTECH
Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results
18 May 2020 //
GLOBENEWSWIRE
Sumitovant Announces Pub of Myovant Abstracts Detailing Additional Efficacy
29 Apr 2020 //
PR NEWSWIRE
Myovant Sciences Announces Publication of Abstracts Detailing Efficacy
27 Apr 2020 //
GLOBENEWSWIRE
Myovant Squares Off with AbbVie On Endometriosis Treatment
27 Apr 2020 //
FOOL
Sumitovant Reports Key Clinical and Regulatory Milestones by Myovant Sciences
24 Apr 2020 //
PR NEWSWIRE
Myovant Sciences Submits (NDA) to the FDA for Once-Daily, Oral RelugoliX
21 Apr 2020 //
PRESS RELEASE
Myovant grabs $40M upfront in regional deal for relugolix
31 Mar 2020 //
ENDPTS
Myovant to Seek FDA Approval for Uterine Fibroid Treatment
23 Jul 2019 //
BIOSPACE
Myovant hits goal in uterine fibroid phase 3
15 May 2019 //
FIERCE BIOTECH
